About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Advances in Therapy
›
Top Articles
Advances in Therapy
4.1
(top 3%)
Impact Factor
4.6
(top 3%)
extended IF
71
(top 6%)
H-Index
1.9K
authors
3.1K
papers
42.6K
citations
5.9K
citing journals
34.3K
citing authors
Most Cited Articles of Advances in Therapy
Title
Year
Citations
Chronic Wound Healing: A Review of Current Management and Treatments
2017
688
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
2013
355
Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights
2014
259
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
2017
232
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
2017
227
Effects of common ophthalmic preservatives on ocular health
2001
213
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives
2016
211
Medication adherence and persistence: a comprehensive review
2005
207
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy
2011
197
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
2018
193
Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension
2001
188
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
2017
179
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
2011
169
DPP-4 inhibitors and lipids: systematic review and meta-analysis
2012
155
Sepsis: A Review of Advances in Management
2017
144
Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis
2009
141
A review of uric acid, crystal deposition disease, and gout
2015
140
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease
2010
140
Validation of an overactive bladder awareness tool for use in primary care settings
2005
140
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
2011
136
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain
2010
134
Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids
2000
133
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
2015
131
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
2017
126
A Review of Chronic Granulomatous Disease
2017
126
previous
2018
2019
2020
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.